Market Overview

Analyst: Morphosys Is Well-Positioned To Continue Success With Antibody Discovery Platforms

Share:
Analyst: Morphosys Is Well-Positioned To Continue Success With Antibody Discovery Platforms
Related
28 Stocks Moving In Monday's Pre-Market Session
The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs

Morphosys AG/S ADR (NASDAQ: MOR) is a German biotech company that specializes in antibodies research. With the expiry of the IPO quiet period, analysts began coverage on U.S.-listed shares.

The Analyst

JMP Securities analyst Konstantinos Aprilakis initiated coverage of Morphosys with a Market Outperform rating and $38 price target.

The Thesis

Morphosys has a "broad pipeline," and two distinct businesses, namely proprietary development and partnered discovery, wherein it works with partners on targets identified by the latter, Aprilakis said in a note. The company's proprietary unit focuses on oncology and inflammation.

Aprilakis noted the company is developing MOR208, its most advanced proprietary asset, which has been tested in combination of lenalidomide for treating relapsed or refractory diffuse large B cell lymphoma. The candidate has received breakthrough designation status from the FDA due to it targeting an unmet medical need.

The analyst expects a commercial launch for MOR208 in 2020, and estimates peak U.S. sales of $1 billion in 2026.

Tremfya, developed by Johnson & Johnson (NYSE: JNJ)'s Janssen unit and generated by Morphosys' technology platform, was approved to treat moderate-to-severe plaque psoriasis in both the U.S. and EU in 2017. The analyst said Morphosys stands to gain about 4.5 percent in royalties on potential U.S. sales of $3.2 billion in 2026.

"In possession of one of the most prolific antibody platforms in all of biotech, Morphosys boasts an expansive and robust pipeline," JMP said.

The Price Action

After ending with a gain of 5.07 percent on their debut on April 19, shares of Morphosys have added 4.1 percent.

The stock traded around $27 at time of publication, down 1.4 percent on the day.

Editor's note: A previous version of this article incorrectly stated the analyst started coverage with a Market Perform rating.

Related Links:

The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Attention Biotech Investors: Mark Your Calendar For These May PDUFA Action Dates

Latest Ratings for MOR

DateFirmActionFromTo
Nov 2018JP MorganMaintainsOverweightOverweight
Nov 2018PiperJaffrayInitiates Coverage OnOverweight
May 2018JMP SecuritiesInitiates Coverage OnMarket Outperform

View More Analyst Ratings for MOR
View the Latest Analyst Ratings

Posted-In: JMP Securities Konstantinos AprilakisAnalyst Color Initiation Analyst Ratings Best of Benzinga

 

Related Articles (MOR + JNJ)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
TVPTImperial CapitalDowngrades15.8
ACORGoldman SachsDowngrades10.0
APTIJefferiesDowngrades38.0
BCOVB. Riley FBRUpgrades12.0
CAMPFirst AnalysisDowngrades22.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

'A Good Time To Buy Equipment Stocks': Citi Upgrades Lam Research, Updates Sector Model

Reactions To Tim Cook's Duke Commencement Speech